Enovis to Acquire eCential Robotics for $180 Million
Enovis is set to acquire French surgical robotics company eCential Robotics in a deal valued at nearly $180 million upfront, strengthening its push into robotic-assisted orthopedic surgery.
The US medical technology company has made a binding offer to acquire eCential for an upfront enterprise value of €155 million, equivalent to about $180 million. The transaction also includes up to €35 million in additional payments tied to development milestones and is expected to close by the end of 2026, subject to regulatory approvals.
The acquisition will bring robotic automation into Enovis' ASTRA enabling technology platform, which already includes its ARVIS augmented reality system and surgical planning capabilities. The combined technology is intended to give surgeons a broader set of precision tools for orthopedic procedures.
eCential Brings Surgical Robotics Expertise
eCential Robotics has spent more than 15 years developing computer-assisted surgery and orthopedic robotics technologies. The Grenoble-based company has built a modular robotic platform combining robotics engineering, software and surgical automation.
The company has also developed technology used in Johnson & Johnson's Velys Spine surgical robot, giving it experience in taking robotic systems from development into clinical applications. eCential currently has about 50 employees in France working across engineering, software, hardware development, manufacturing and regulatory operations.
Enovis plans to establish a robotics centre of excellence in Grenoble following the acquisition. The company expects the French engineering team and its existing intellectual property to become a central part of its robotics development strategy.
Knee and Shoulder Robots in Development
The acquisition is also expected to accelerate Enovis' plans to introduce new robotic systems for orthopedic surgery.
The company is targeting a knee surgery robot for launch in late 2028, followed by a shoulder robot in 2029. The systems are expected to build on eCential's robotic platform while integrating with Enovis' existing surgical technologies.
Shoulder surgery is a particularly important target for the company. Enovis sees room to differentiate its planned system through a robotic arm with seven degrees of freedom, which could provide surgeons with greater flexibility during procedures.
The company already competes in orthopedic medical technology, while major players including Stryker, Johnson & Johnson and Zimmer Biomet have been expanding their own robotic surgery portfolios. Bringing eCential's technology into Enovis gives the company a way to accelerate its development rather than building a robotics platform entirely from scratch.
Robotics Becomes a Bigger Part of Enovis' Strategy
The acquisition expands Enovis' focus from traditional orthopedic devices and augmented-reality tools toward a more integrated surgical technology ecosystem.
By combining robotic assistance, augmented reality and procedure-planning software, Enovis aims to give surgeons more connected tools inside the operating room. The company expects the technology to support greater surgical precision and more streamlined workflows while helping it develop new robotic applications.
The financial impact will initially put some pressure on Enovis' margins. The company expects roughly 150 basis points of deal-related adjusted EBITDA margin dilution in 2027, partly offset by underlying improvement, resulting in an expected 100-basis-point headwind. It expects year-over-year margin improvement to resume in 2028.
For Enovis, the acquisition is ultimately a bet that surgical robotics will become a more important part of orthopedic care. By bringing eCential's engineering and robotics capabilities in-house, the company can move more quickly on its planned knee and shoulder systems while building a broader technology platform around surgeons' workflows. The deal therefore puts robotics closer to the centre of Enovis' long-term strategy as competition in robotic-assisted surgery continues to expand.
